STAT Plus: ICER, the controversial cost-effectiveness watchdog, reverses course on two migraine drugs
In an unusual move, the Institute for Clinical and Economic Review has reversed course and decided a pair of new drugs for treating acute migraine attacks have greater value than thought initially. And the cost-effectiveness watchdog is pointing to its decision as an example of its willingness to exercise greater flexibility in the face of long-standing criticism of its approach to evaluating new medicines.
The nonprofit reassessed the drugs — Ubrelvy from Allergan (AGN) and another from Biohaven Pharmaceuticals that is not yet available — after reviewing a re-analysis of clinical trials it asked Allergan to conduct. ICER determined the Allergan tablet deserved a revised value closer to the $4,900 list price. Given both drugs are quite similar, ICER also determined the Biohaven drug should be priced the same.
Continue to STAT Plus to read the full story…
